NCT03103724已完成2 期
A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano1 个研究点 分布在 1 个国家目标入组 68 人开始时间: 2017年3月16日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 68
- 试验地点
- 1
- 主要终点
- Disease Control Rate (DCR)
研究概览
简要总结
Open label, single arm, phase II multicentre study designed to determine the clinical benefit, as measured by 3-months disease control rate (DCR) provided by enzalutamide in metastatic Castration Resistant Prostate Cancer patients with at least one visceral site involvement.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •ECOG PS 0-1-2
- •Biopsy (primary tumour or metastases) confirming the diagnosis of prostate adenocarcinoma
- •Documented measurable metastatic visceral disease (according to RECIST 1.1 criteria) considering metastases in lung or liver or extraregional lymphnodes
- •Written informed consent
- •Platelets > or = 100 x109/L; haemoglobin > or = 9 g/dl; neutrophils > or 1.5 x 109/L
- •Bilirubin < or = 2 mg/dl, AST and ALT < or = 2.5 times the UNL or < or = 5 times UNL for pts with liver metastases; serum albumin > or = the LNL
- •Patients of childbearing age should use contraceptive methods
- •Life expectancy > 3 months
- •Able to swallow the study drug and comply with study requirements;
- •Willing and able to give informed consent.
- •Ongoing androgen deprivation therapy with a GnRH analogue or orchiectomy (i.e., surgical or medical castration);
- •Patients may have received previous therapy including chemotherapy (docetaxel) last cycle must be received 3 weeks before start of experimental treatment. Hormonal treatment containing bicalutamide must be interrupted 2 weeks before start of study therapy
- •Previous radiotherapy (prostate and/or bone) is accepted but must be interrupted 3 weeks before start of experimental treatment.
- •Serum testosterone level < 1.7 nmol/L (50 ng/dL) at the Screening visit
- •Progressive disease by PSA or imaging in the setting of medical or surgical castration. Disease progression for study entry is defined as one or more of the following three criteria (according with PCWG2):
- •PSA progression defined by a minimum of three rising PSA levels with an interval of ≥ 1 week between each determination. The PSA value at the Screening visit should be ≥ 2 g/L (2 ng/ml); if the third PSA value is less than second PSA, a fourth PSA must be repeated and if it the value is higher than second must be considered as disease
- •Soft tissue/visceral disease progression defined by RECIST 1.1;
- •Bone disease progression defined by two or more new lesions on bone scan.
排除标准
- •Severe, concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment;
- •Metastases in the brain or active epidural disease;
- •History of another malignancy within the previous 5 years other than curatively treated non-melanomatous skin cancer;
- •History of seizure, including any febrile seizure, loss of consciousness, or transient ischemia attack within 12 months of enrollment (Day 1 visit), or any condition that may pre-dispose to seizure (e.g., prior stroke, head trauma with loss of consciousness requiring hospitalization);
- •Clinically significant cardiovascular disease including: Myocardial infarction within 6 months; Uncontrolled angina within 3 months; Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or patients with history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multi-gated acquisition scan (MUGA) performed within 3 months results in a left ventricular ejection fraction that is ≥ 45%;
- •Diagnosed or suspected congenital long QT syndrome;
- •History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes);
- •Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer within last 3 months);
- •Major surgery within 4 weeks prior to enrollment (Day 1 visit);
- •Prior treatment with abiraterone acetate;
- •Participation in a clinical trial about an experimental anti-androgen agent (eg. ARN-509, ODM-201, VT-464, except for placebo arm);
- •Treatment (concomitant or in the previous 2 weeks) with anti-androgens (eg. Bicalutamide, nilutamide, flutamide) or 5-a reductase inhibitors (eg. finasteride, dutasteride).
研究组 & 干预措施
Enzalutamide
Experimental
All subjects will receive open label enzalutamide 160 mg (4 x 40 mg capsules), orally once daily.
干预措施: Xtandi (Drug)
结局指标
主要结局
Disease Control Rate (DCR)
时间窗: 3 months
To determine the clinical benefit, as measured by 3 months disease control rate (DCR) provided by enzalutamide in mCRPC patients with visceral disease.
次要结局
- Pain assessment(2 years)
- Safety of the treatment per NCI-CTCA v. 4.0(2 years)
- Quality of life by EQ-5D-5L e FACT-P(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic CancerPancreatic NeoplasmsNCT05481463Sun Yat-sen University22
Unknown
2 期
A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCLRR DLBCL; PD-1; CD20NCT05178836Shandong New Time Pharmaceutical Co., LTD62
已完成
2 期
Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic AdenocarcinomaPancreatic AdenocarcinomaNCT01558869The University of Hong Kong37
已完成
2 期
Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal CancerColorectal CancerNCT03146377The University of Hong Kong32
已完成
2 期
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBCTriple Negative Breast CancerMetastatic Breast CancerAdvanced Breast CancerNCT04408118MedSIR100